Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

enGene Holdings Inc. - Common Stock (NQ: ENGN )

4.000 +0.010 (+0.25%)
Streaming Delayed Price Updated: 11:24 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,216
Open 3.990
Bid (Size) 3.910 (1)
Ask (Size) 4.000 (2)
Prev. Close 3.990
Today's Range 3.920 - 4.390
52wk Range 3.500 - 16.62
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
From enGene Holdings Inc.
Via Business Wire

Performance

YTD
-43.34%
-43.34%
1 Month
-13.61%
-13.61%
3 Month
-42.45%
-42.45%
6 Month
-57.17%
-57.17%
1 Year
-73.79%
-73.79%

More News

Read More
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in the Leerink Partners Global Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Reports Full Year 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From enGene Holdings Inc.
Via Business Wire
Why enGene Holdings Stock Is Trading Higher
Via Benzinga
enGene Announces $60 Million Private Placement Financing
From enGene Holdings Inc.
Via Business Wire
IBM Posts Weak Sales, Joins Garrett Motion, Beyond And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer
From enGene Holdings Inc.
Via Business Wire
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort
From enGene Holdings Inc.
Via Business Wire
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
From enGene Holdings Inc.
Via Business Wire
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From enGene Holdings Inc.
Via Business Wire
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
From enGene Holdings Inc.
Via Business Wire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.